Clinical trials: Stage IV Cancer (Solid Tumors Only)
Advanced Solid Tumors
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy…
- Trial name
- NCT05599984
- Testing
- ABBV-706, Cisplatin, Budigalimab
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 288 people
- Sponsor
- AbbVie
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
TRX518-001 is an open label, non-randomized single group assignment, Phase 1 single dose escalation study in adults with biopsy proven unresectable Stage III or Stage IV melanoma or other solid tumor malignancies.
- Trial name
- TRX518-001 (NCT01239134)
- Testing
- TRX518
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Leap Therapeutics, Inc.
Neoplasms
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors
This Phase I, open-label, multicenter study will evaluate the pharmacokinetics, safety, and preliminary anti-tumor activity of atezolizumab as monotherapy in Chinese participants with locally advanced or metastatic gastric…
- Trial name
- IMYO29233 (NCT02825940)
- Testing
- Atezolizumab, Gemcitabine, Cisplatin
- Where
- 7 sites in China
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in…
- Trial name
- NCT04931823
- Testing
- CPO-100
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Refractory Metastatic Colorectal Cancer, Solid Tumor
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients.
- Conditions
- Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient
- Trial name
- NCT05205330
- Testing
- CR6086, AGEN2034
- Where
- 3 sites in Italy
- Volunteers
- 107 people
- Sponsor
- Rottapharm Biotech
PD-L1-selected Solid Tumors
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected…
- Trial name
- SKYSCRAPER-11 (NCT05661578)
- Testing
- Tiragolumab and Atezolizumab IV FDC
- Where
- 32 sites in United States, China and 7 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by…
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- STEALTH-001 (NCT06444815)
- Testing
- VET3-TGI, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- KaliVir Immunotherapeutics
Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
The purpose of this study is to determine if Itacitinib in combination with erlotinib is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB/Stage IV or recurrent whose tumors…
- Trial name
- NCT02355431
- Testing
- Itacitinib, erlotinib
- Where
- United States
- Sponsor
- Incyte Corporation
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H)
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
- Trial name
- IGNYTE (NCT03767348)
- Testing
- RP1, nivolumab
- Where
- 51 sites in United States, France and 3 more
- Volunteers
- 340 people
- Sponsor
- Replimune, Inc.
Melanoma Stage IV, Solid Tumor
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy.
- Trial name
- NCT06425926
- Testing
- GIM-531, Anti-PD-1 monoclonal antibody
- Where
- 11 sites in United States
- Volunteers
- 117 people
- Sponsor
- Georgiamune Inc
Malignant Solid Tumors
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.
- Trial name
- NCT02805166
- Testing
- PEG-rhG-CSF
- Volunteers
- 420 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT04721015
- Testing
- ABBV-637, Docetaxel, Osimertinib
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Stage IV Cancer (Solid Tumors Only), Survival
Observational Study of Survival Outcomes of Stage IV Cancer Patients
Patients diagnosed with Stage IV cancer (solid tumors only) are evaluated to determine whether they are candidates for traditional chemotherapy.
- Trial name
- NCT01843985
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cure Cancer Worldwide Corporation
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
- Trial name
- NCT03425279
- Testing
- CAB-AXL-ADC, PD-1 inhibitor
- Where
- 40 sites in United States, Hong Kong and 1 more
- Volunteers
- 245 people
- Sponsor
- BioAtla, Inc.
Cancer
A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours
Two-centre, open-label, non-randomized, dose-finding phase I study to determine the MTD of E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days in patients with solid tumors, for…
- Trial name
- NCT00459823
- Testing
- E7107
- Where
- 2 sites in Netherlands, Spain
- Volunteers
- 40 people
- Sponsor
- Eisai Limited